(Q35580126)

9 August 2017

1 reference

title

Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure (English)

1 reference

9 August 2017

Interaction of -blockers and angiotensin receptor blockers/ACE inhibitors in heart failure (English)

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.021

30 March 2024

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.021

30 March 2024

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.021

30 March 2024

author name string

Jay N. Cohn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14608516

30 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14608516

30 March 2024

publication date

1 September 2003

1 reference

full work available at URL

9 August 2017

https://doi.org/10.3317/jraas.2003.021

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14608516

http://journals.sagepub.com/doi/pdf/10.3317/jraas.2003.021

30 March 2024

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.021

Journal of the Renin-Angiotensin-Aldosterone System

30 March 2024

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

137-139

1 reference

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Effect of carvedilol on survival in severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.021

Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis

21 January 2018

13

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.021

beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure

30 March 2024

15

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.021

Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure

30 March 2024

20

1 reference

https://api.crossref.org/works/10.3317/JRAAS.2003.021

30 March 2024

Identifiers

1 reference

9 August 2017

1 reference